102 related articles for article (PubMed ID: 23395558)
1. Expression and potential role of ErbB receptors in type II endometrial cancer.
Androutsopoulos G; Adonakis G; Liava A; Ravazoula P; Decavalas G
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):204-8. PubMed ID: 23395558
[TBL] [Abstract][Full Text] [Related]
2. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.
Suo Z; Risberg B; Kalsson MG; Willman K; Tierens A; Skovlund E; Nesland JM
J Pathol; 2002 Jan; 196(1):17-25. PubMed ID: 11748637
[TBL] [Abstract][Full Text] [Related]
3. Expression of the epidermal growth factor system in endometrial cancer.
Adonakis G; Androutsopoulos G; Koumoundourou D; Liava A; Ravazoula P; Kourounis G
Eur J Gynaecol Oncol; 2008; 29(5):450-4. PubMed ID: 19051810
[TBL] [Abstract][Full Text] [Related]
4. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell JA; Rampaul RS; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
Br J Cancer; 2004 Oct; 91(8):1532-42. PubMed ID: 15480434
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
[TBL] [Abstract][Full Text] [Related]
6. ErbB2, ErbB3 and ErbB4 expression in urothelial tumors of the upper urinary tract and their prognostic significance.
Galanakis I; Spyropoulos E; Gkialas I; Nomikos A; Souka E; Mitropoulos D
J BUON; 2013; 18(3):653-9. PubMed ID: 24065479
[TBL] [Abstract][Full Text] [Related]
7. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
8. Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration.
Takagi K; Miki Y; Tanaka S; Hashimoto C; Watanabe M; Sasano H; Ito K; Suzuki T
Endocr J; 2016; 63(3):287-99. PubMed ID: 26842712
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor immunostaining and epidermal growth factor receptor-tyrosine kinase activity in proliferative and neoplastic human endometrium.
Miturski R; Semczuk A; Postawski K; Jakowicki JA
Tumour Biol; 2000; 21(6):358-66. PubMed ID: 11006576
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
12. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium.
Brys M; Semczuk A; Rechberger T; Krajewska WM
Oncol Rep; 2007 Jul; 18(1):261-5. PubMed ID: 17549377
[TBL] [Abstract][Full Text] [Related]
13. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
[TBL] [Abstract][Full Text] [Related]
14. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
15. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer.
Srinivasan R; Benton E; McCormick F; Thomas H; Gullick WJ
Clin Cancer Res; 1999 Oct; 5(10):2877-83. PubMed ID: 10537356
[TBL] [Abstract][Full Text] [Related]
16. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
17. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
18. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
20. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
